ApoA-I Cleaved by Transthyretin Has Reduced Ability to Promote Cholesterol Efflux and Increased Amyloidogenicity
Overview
Affiliations
A fraction of plasma transthyretin (TTR) circulates in HDL through binding to apolipoprotein A-I (apoA-I). Moreover, TTR is able to cleave the C terminus of lipid-free apoA-I. In this study, we addressed the relevance of apoA-I cleavage by TTR in lipoprotein metabolism and in the formation of apoA-I amyloid fibrils. We determined that TTR may also cleave lipidated apoA-I, with cleavage being more effective in the lipid-poor prebeta-HDL subpopulation. Upon TTR cleavage, discoidal HDL particles displayed a reduced capacity to promote cholesterol efflux from cholesterol-loaded THP-1 macrophages. In similar assays, TTR-containing HDL from mice expressing human TTR in a TTR knockout background had a decreased ability to perform reverse cholesterol transport compared with similar particles from TTR knockout mice, reinforcing the notion that cleavage by TTR reduces the ability of apoA-I to promote cholesterol efflux. As amyloid deposits composed of N-terminal apoA-I fragments are common in the atherosclerotic intima, we assessed the impact of TTR cleavage on apoA-I aggregation and fibrillar growth. We determined that TTR-cleaved apoA-I has a high propensity to form aggregated particles and that it formed fibrils faster than full-length apoA-I, as assessed by electron microscopy. Our results show that apoA-I cleavage by TTR may affect HDL biology and the development of atherosclerosis by reducing cholesterol efflux and increasing the apoA-I amyloidogenic potential.
A review of cutting-edge biomarkers for diagnosing coronary artery disease.
Azami P, Mohammadzadeh S, Seirafi S, Razeghian-Jahromi I Medicine (Baltimore). 2025; 104(4):e41377.
PMID: 39854741 PMC: 11771658. DOI: 10.1097/MD.0000000000041377.
Tetrameric Transthyretin as a Protective Factor Against Alzheimer's Disease.
Corino C, Aimo A, Luigetti M, Ciccone L, Ferrari Chen Y, Panichella G Mol Neurobiol. 2024; 62(3):2945-2954.
PMID: 39192044 PMC: 11790689. DOI: 10.1007/s12035-024-04442-8.
Cho K, Bahuguna A, Lee Y, Lee S, Dominguez-Horta M, Martinez-Donato G Int J Mol Sci. 2024; 25(10).
PMID: 38791598 PMC: 11121824. DOI: 10.3390/ijms25105560.
Zhibo W, Ying L, Daoping W, Bo M, Lan M, Junguo R J Tradit Chin Med. 2024; 44(3):554-563.
PMID: 38767640 PMC: 11077157. DOI: 10.19852/j.cnki.jtcm.20240408.001.
Lipoproteins and Calcific Aortic Valve Disease: Hardening Evidence?.
OBrien K Arterioscler Thromb Vasc Biol. 2022; 42(11):1321-1323.
PMID: 36134565 PMC: 9613592. DOI: 10.1161/ATVBAHA.122.318310.